An interventional study of Shenqi Yishen Granules and Placebo in IgA Nephropathy (IgAN), sponsored by Keda Lu. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Keda Lu · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn if Shenqi Yishen Granules works to treat IgA Nephropathy in adults. It will also learn about the safety of Shenqi Yishen Granules. The main questions it aims to answer are:
Does Shenqi Yishen Granules lower 24-hour urinary protein quantification of participants? What medical problems do participants have when taking Shenqi Yishen Granules? Researchers will compare Shenqi Yishen Granules to a placebo (a look-alike substance that contains no drug) to see if Shenqi Yishen Granules works to treat IgA Nephropathy.
254 studies on the registry are indexed under Glomerulonephritis, IGA; 100 are open to participants now.
This study's planned enrollment of 102 is above the median of 70 across 206 interventional studies indexed under Glomerulonephritis, IGA.
Browse Glomerulonephritis, IGA studies →This is the only study on the registry with Keda Lu as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Shenqi Yishen Granules + Irbesartan
Drug: Shenqi Yishen Granules
Chinese herbal placebo + Irbesartan
Drug: Placebo
A traditional Chinese medicine compound for the treatment of IgA nephropathy
Also known as: Irbesartan
a look-alike substance that contains no drug
Also known as: Irbesartan
24-hour urinary protein quantification
24-hour urinary protein quantification
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Protein-to-creatinine rati
Concentration of Protein-to-creatinine rati
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Red blood cells in urine
Red blood cells in urine
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Glomerular filtration rate
Glomerular filtration rate
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
The number of infections in the respiratory, gastrointestinal, or urinary tract
The number of infections in the respiratory, gastrointestinal, or urinary tract
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
TCM syndrome score
Assess the patient's clinical symptoms based on the rating scale; the higher the score, the more severe the symptoms.
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Concentration of Potassium
Safety indicators
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
electrocardiogram
Determine whether the patient has experienced adverse cardiac events based on the electrocardiogram
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Concentration of Alanine Aminotransferase
Safety indicators
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Concentration of Glutamic-oxaloacetic transaminase
Security indicators
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Concentration of hemoglobin
Security indicators
Time frame: 0 weeks, 4weeks, 8 weeks, 12 weeks
No study locations are listed for this record.
Plan to share: No — Individual participant data involves the personal privacy of participants and should not be made public or shared.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.